Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor
Authors:
Open Access
- 1 August 2017
- journal article
- Published by SAGE Publications in Rare Tumors
- Vol. 9 (2) , 47-49
Abstract
Testicular germ cell tumor (GCT) is the most common malignancy in young males between the ages of 15 to 35 years. Although the overall cure rate of GCTs approaches 95%, almost 25% of patients with distant metastases die from the cancer. Active investigations on novel treatment options for platinum-refractory GCTs include immunotherapies such as program-death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors. In this case, we report a patient with metastatic GCTs who was treated with pembrolizumab, a PD-L1 inhibitor, in a phase II study after failing several lines of chemotherapy. We highlighted the rationale for the use of PD-L1 inhibitor in this population.Keywords
This publication has 20 references indexed in Scilit:
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International DatabaseJournal of Clinical Oncology, 2011
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)British Journal of Cancer, 2011
- TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor AnalysisJournal of Clinical Oncology, 2010
- Development of Cell-Cycle Inhibitors for Cancer TherapyCurrent Oncology, 2009
- Treatment of Growing Teratoma SyndromeNew England Journal of Medicine, 2009
- High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell TumorsNew England Journal of Medicine, 2007
- A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumoursAnnals of Oncology, 2005
- Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II studyAnnals of Oncology, 2004
- Candidate Genes for Testicular Cancer Evaluated by In Situ Protein Expression Analyses on Tissue MicroarraysNeoplasia, 2003